

DAFTAR PUSTAKA

- Altamura, C., Fagiolini, A., Galderisi, S., Rocca, P., Rossi, A., 2014. Schizophrenia today: Epidemiology, diagnosis, course and models of care. *J. Psychopathol.* **20**, 223–243.
- American Psychiatric Association, 2013. Schizophrenia spectrum and other psychotic disorders, In: *Diagnostic and Statistical Manual of Mental Disorders*. American Psychiatric Publishing, Washington DC, pp. 87–122.
- Amir, N., 2013. Skizofrenia. In: *Buku Ajar Psikiatri*. Badan Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta, p. 173.
- Amr, M., Lakhan, S.E., Sanhan, S., Al-Rhaddad, D., Hassan, M., Thiabh, M., Shams, T., 2013. Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia. *Int. Arch. Med.* **6**, 1–8.
- Andreasen N.C., 1982. Negative Symptoms in Schizophrenia. Definition and reliability. *Arch. Gen. Psychiatry* **39**, 784–788.
- Arif, I.S., 2006. Skizofrenia. In: *Skizofrenia: Memahami Dinamika Keluarga Pasien*. Rafika Aditama, Bandung, pp. 20–30.
- Ayano, G., 2016. First Generation Antipsychotics: Pharmacokinetics, Pharmacodynamics, Therapeutic Effects and Side Effects: A Review. *J. Chem.* **5**, 53–63.
- Baker, J.D., 2016. The Purpose, Process, and Methods of Writing a Literature Review. *AORN J.* **103**, 265–269.
- Barkan, T., Peled, A., Modai, I., Weizman, A., Rehavi, M., 2006. Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals. *Eur. Neuropsychopharmacol.* **16**, 429–436.
- Bobes, J., A-Portilla, M.P.G., Rejas, J., Ndez, G.H., Garcia-Garcia, M., Rico-Villademoros, F., *et al.*, 2003. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. *J. Sex Marital Ther.* **29**, 125–147.
- Bonoldi, I., Simeone, E., Rocchetti, M., Codjoe, L., Rossi, G., Gambi, F., *et al.*, 2013. Prevalence of self-reported childhood abuse in psychosis: A meta-analysis of retrospective studies. *Psychiatry Res.* **210**, 8–15.
- Bourne, H.R., Zastrow, M. V., 2010. Reseptor Obat dan Farmakodinamik. In: Katzung, B.G. (Ed.), *Farmakologi Dasar & Klinik*. Bursa Ilmu, Jakarta, p. 16.
- Brébion, G., Smith, M.J., Amador, X., Malaspina, D., Gorman, J.M., 1997. Clinical correlates of memory in schizophrenia: Differential links between depression, positive and negative symptoms, and two types of memory impairment. *Am. J. Psychiatry* **154**, 1538–1543.
- Brisch, R., Saniotis, A., Wolf, R., Biela, H., Bernstein, H.G., Steiner, J., *et al.*, 2014. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: Old fashioned, but still in vogue. *Front. Psychiatry* **5**, 1–11.

- British Medical Association, 2015. Central nervous system. In: *British National Formulary*. Pharmaceutical Press, London, pp. 242–246.
- Buoli, M., Kahn, R.S., Serati, M., Altamura, A.C., Cahn, W., 2016. Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia. *Hum. Psychopharmacol.* **31**, 325–331.
- Chaves, K.M., Serrano-Blanco, A., Ribeiro, S.B., Soares, L.A.L., Guerra, G.C.B., Do Socorro C.F.A, M., *et al.*, 2013. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. *Psychiatr. Q.* **84**, 125–135.
- Chikowe, I., Domingo, M., Mwakaswaya, V., Parveen, S., Mafuta, C., Kampira, E., 2019. Adverse drug reactions experienced by out-patients taking chlorpromazine or haloperidol at Zomba Mental Hospital, Malawi. *BMC Res. Notes* **12**, 1–6.
- Conley, R.R., Kelly, D.L., Nelson, M.W., Richardson, C.M., Feldman, S., Benham, R., *et al.*, 2005. Risperidone, Quetiapine, and Fluphenazine in the Treatment of Patients With Therapy-Refractory Schizophrenia. *Clin. Neuropharmacol.* **28**, 163–168.
- Crespo-Facorro, B., Ortiz-Garcia D.L.F, V., Mata, I., Ayesa-Arriola, R., Suarez-Pinilla, P., Valdizan, E.M., *et al.*, 2014. Treatment of first-episode non-affective psychosis: A randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. *Psychopharmacology (Berl)*. **231**, 357–366.
- Darsana, I.W., Suariyani, N.L.P., 2020. Trend Karakteristik Demografi Pasien Skizofrenia di Rumah Sakit Jiwa Provinsi Bali (2013-2018). *Arc. Com. Heal.* **7**, 41–51.
- De Greef, R., Maloney, A., Olsson-Gisleskog, P., Schoemaker, J., Panagides, J., 2011. Dopamine D2 occupancy as a biomarker for antipsychotics: Quantifying the relationship with efficacy and extrapyramidal symptoms. *AAPS J.* **13**, 121–130.
- Debbané, M., Barrantes-Vidal, N., 2015. Schizotypy from a developmental perspective. *Schizophr. Bull.* **41**, S386–S395.
- Dold, M., Samara, M.T., Li, C., Tardy, M., Leucht, S., 2015. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. *Cochrane Database Syst. Rev.* **1**.
- Eggers, A.E., 2013. A serotonin hypothesis of schizophrenia. *Med. Hypotheses* **80**, 791–794.
- Ernest, D., Olga Vuksic, R., Ashley Shepard-Smith, Ms., Emily Webb, R., Reg, O., 2017. *Schizophrenia: An information guide*. Centre and Addiction for Mental Health, Canada.
- Faden, J., Citrome, L., 2019. Resistance is not futile: treatment-refractory schizophrenia—overview, evaluation and treatment. *Expert Opin. Pharmacother.* **20**, 11–24.
- Ferrari, R., 2015. Writing narrative literature reviews. *Eur. Med. Writ. Assoc.* **24**, 230–235.
- Fulford, D., Pearson, R., Stuart, B.K., Fisher, M., Mathalon, D.H., Vinogradov, S.,

- et al.*, 2014. Symptom assessment in early psychosis: The use of well-established rating scales in clinical high-risk and recent-onset populations. *Psychiatry Res.* **220**, 1077–1083.
- Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., *et al.*, 2016. *Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders*, Australian and New Zealand Journal of Psychiatry.
- Gejman, P. V., Sanders, A.R., Duan, J., 2010. The role of genetics in the etiology of schizophrenia. *Psychiatr. Clin. North Am.* **33**, 35–66.
- Gibert, J., Giner, J., Bobes, J., Tafalla, M., Herranz, S., Ovejero, C., *et al.*, 2007. The “Seroquel” Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia. *Int. J. Psychiatry Clin. Pract.* **11**, 222–232.
- Grattan, D.R., Jasoni, C.L., Liu, X., Anderson, G.M., Herbison, A.E., 2007. Prolactin Regulation of Gonadotropin-Releasing Hormone Neurons to Suppress Luteinizing Hormone Secretion in Mice. *Endocrinology* **148**, 4344–4351.
- Guo, X., Fang, M., Zhai, J., Wang, B., Wang, C., Hu, B., 2011. Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. *Psychopharmacology (Berl.)* **216**, 475–484.
- Habil, M.H., Gondoyoewono, H., Chaudhry, H.R., Samanwongthai, U., Hamid, A.R.A., Hashmi, I.T., *et al.*, 2007. Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia. *Int. J. Clin. Pharmacol. Ther.* **45**, 631–642.
- Haddad, P.M., Correll, C.U., 2018. Therapeutic Advances in Psychopharmacology The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. *Ther Adv Psychopharmacol* **8**, 303–318.
- Hahn, M., Chintoh, A., Giacca, A., Xu, L., Lam, L., Mann, S., *et al.*, 2011. Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: An animal model. *Schizophr. Res.* **131**, 90–95.
- Heinz, A., Deserno, L., Reininghaus, U., 2013. Urbanicity, social adversity and psychosis. *World Psychiatry* **12**, 187–197.
- Holt, R.I.G., 2019. Association Between Antipsychotic Medication Use and Diabetes. *Curr. Diab. Rep.* **19**, 1–10.
- Hong, L.S., Kinon, B.J., Tennant, C.J., Sniadecki, J., Volavka, J., 2009. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. *Neuropsychiatr. Dis. Treat.* **5**, 47–54.
- Inoue, I., Yanai, K., Kitamura, D., Taniuchi, I., Kobayashi, T., Niimura, K., Watanabe, Takehiko, Watanabe, Takeshi, 1996. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 13316–13320.
- Jablensky, A., 2006. Subtyping schizophrenia: Implications for genetic research.

- Mol. Psychiatry* **11**, 815–836.
- James, S.L., Abate, D., Abate, K.H., Abay, S.M., Abbafati, C., Abbasi, N., *et al.*, 2018. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **392**, 1789–1858.
- Javitt, D.C., 2006. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. *Curr. Opin. Psychiatry* **19**, 151–157.
- Jindal, K.C., Singh, G.P., Munjal, V., 2013. Aripiprazole versus olanzapine in the treatment of schizophrenia: A clinical study from India. *Int. J. Psychiatry Clin. Pract.* **17**, 21–29.
- Kahn, R.S., Fleischhacker, W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P.M., *et al.*, 2008. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet* **371**, 1–13.
- Kapur, S., Zipursky, R., Jones, C., Remington, G., Houle, S., 2000. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. *Am. J. Psychiatry* **157**, 514–520.
- Katzung, B.G., 2010. Prinsip Dasar: Pendahuluan. In: Katzung, B.G. (Ed.), *Farmakologi Dasar & Klinik*. Bursa Ilmu, Jakarta, p. 5.
- Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr. Bull.* **13**, 261–276.
- Kementerian Kesehatan Republik Indonesia, 2013. Riset Kesehatan Dasar. Lap. Riskesdas.
- Kementerian Kesehatan Republik Indonesia, 2018. Riset Kesehatan Dasar. Lap. Riskesdas 53, 181–222.
- Kim, R., Skolnick, J., 2008. Assessment of Programs for Ligand Binding Affinity Prediction. *J. Comput. Chem.* **29**, 1316–1331.
- Kishimoto, T., Agarwal, V., Kishi, T., Leucht, S., Kane, J.M., Corell, C.U., 2013. Relapse Prevent in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics. *Mol. Psychiatry* **18**, 53–66.
- Kroeze, W.K., Husein, S.J., Popadak, B.A., Renock, S.A., Steinberg, S., Ernsberger, P., *et al.*, 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. *Neuropsychobiology* **28**, 519–526.
- Kumar, M., Chavan, B.S., Sidana, A., Das, S., 2017. Efficacy and Tolerability of Clozapine versus Quetiapine in Treatment-resistant Schizophrenia. *Indian Psychiatr. Soc.* **39**, 770–776.
- Kumar, S.V.S., Sinha, V.K., 2015. Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. *Indian J. Psychiatry* **57**, 386–391.

- Kumar, S., Pandey, R.S., Thirthalli, J., Kumar, Siva, Kumar, N., 2017. A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia. *Curr. Neuropharmacol.* **15**, 1073–1084.
- Lehman, A.F., Lieberman, J.A., Dixon, L.B., McGlashan, T.H., Miller, A.L., Perkins, D.O., Kreyenbuhl, J., 2010. Treatment Recommendations for Patients with Schizophrenia. In: *Practice Guideline for The Treatment of Patients with Schizophrenia*. American Psychiatric Association, Washington DC, pp. 27–30.
- Lett, T.A.P., Wallace, T.J.M., Chowdhury, N., Tiwari, A.K., Kennedy, J.L., Müller, D.J., 2012. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. *Mol. Psychiatry* **17**, 242–266.
- Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C., Davis, J.M., 2009. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* **373**, 31–41.
- Li, H., Shen, Y., Wang, G., Shi, J., Ma, C., Xie, S., Zhang, H., Wang, X., Li, K., Xu, X., Gu, N., 2018. A 6-week, multicenter, double-blind, double-dummy, chlorpromazine-controlled non-inferiority randomized phase iii trial to evaluate the efficacy and safety of quetiapine fumarate (SEROQUEL) extended-release (XR) in the treatment of patients with schizophr. *Psychiatry Res.* **259**, 117–124.
- Liang, M., Schwickart, M., Schneider, A.K., Vainshtein, I., Nagro, C. Del, Standifer, N., Roskos, L.K., 2016. Receptor Occupancy Assessment by Flow Cytometry as Pharmacodynamic Biomarker in Biopharmaceutical Development. *Cytom. Part B (Clinical Cytom.)* **90**, 117–127.
- Lieberman, J.A., Phillips, M.R., Gu, H., Stroup, T.S., Zhang, P., Kong, L., *et al.*, 2003. Atypical and Conventional Antipsychotic Drugs in Treatment-Naïve First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine vs Chlorpromazine. *Neuropsychopharmacology* **28**, 995–1003.
- Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., *et al.*, 2005. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. *N. Engl. J. Med.* **353**, 1209–1223.
- Maslim, R., 2007. Obat Anti-psikosis. In: *Penggunaan Klinis Obat Psikotropik (Psychotropic Medication)*. PT. Nuh Jaya, Jakarta, pp. 18–26.
- Matei, V.P., Mihailescu, A., Paraschiv, G., Al-Bataineh, R., Purnichi, T., 2016. Weight Gain and Antipsychotics. Data From Eufest Study. *Acta Endocrinol. (Copenh.)* **12**, 177–184.
- Matheson, S.L., Shepherd, A.M., Laurens, K.R., Carr, V.J., 2011. A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. *Schizophr. Res.* **133**, 133–142.
- Matsui-Sakata, A., Ohtani, H., Sawada, Y., 2005a. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. *Drug Metab. Pharmacokinet.* **20**, 187–199.
- Matsui-Sakata, A., Ohtani, H., Sawada, Y., 2005b. Receptor Occupancy-based

- Analysis of the Contributions of Various Receptors to Antipsychotics-induced Weight Gain and Diabetes Mellitus. *Drug Metab. Pharmacokinet.* **20**, 368–378.
- Mauri, M.C., Paletta, S., Maffini, M., Colasanti, A., Dragogna, F., Di Pace, C., Altamura, A.C., 2014. Clinical pharmacology of atypical antipsychotics: An update. *EXCLI J.* **13**, 1163–1191.
- Meltzer, H.Y., 2017. New Trends in the Treatment of Schizophrenia. *CNS Neurol. Disord. - Drug Targets* **16**, 900–906.
- Meyer, J.M., 2001. Novel antipsychotics and severe hyperlipidemia. *J. Clin. Psychopharmacol.* **21**, 369–374.
- Mirabzadeh, A., Kimiaghali, P., Fadal, F., Samiei, M., Daneshmand, R., 2014. The therapeutic effectiveness of risperidone on negative symptoms of schizophrenia in comparison with haloperidol: a randomized clinical trial. *Basic Clin. Neurosci.* **5**, 212–217.
- Möller, H.J., Riedel, M., Jäger, M., Wickelmaier, F., Maier, W., Kühn, K.U., *et al.*, 2008. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-Week results of a randomized controlled trial within the German research network on schizophrenia. *Int. J. Neuropsychopharmacol.* **11**, 985–997.
- Müller, D.J., Kennedy, J.L., 2006. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. *Pharmacogenomics* **7**, 863–887.
- Nagaraj, A.K.M., Pai, N.B., Rao, S., 2009. A comparative study of sexual dysfunction involving risperidone, quetiapine, and olanzapine. *Indian J. Psychiatry* **51**, 265–271.
- Natesan, S., Reckless, G.E., Nobrega, J.N., Fletcher, P.J., Kapur, S., 2006. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: Comparing aripiprazole to other antipsychotics in animal models. *Neuropsychopharmacology* **31**, 1854–1863.
- Newcomer, J.W., Haupt, D.W., Fucetola, R., Melson, A.K., Schweiger, J.A., Cooper, B.P., Selke, G., 2002. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. *Arch. Gen. Psychiatry* **59**, 337–345.
- Nonogaki, K., Strack, A.M., Dallman, M.F., Tecott, L.H., 1998. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT(2C) receptor gene. *Nat. Med.* **4**, 1152–1156.
- Nord, M., Farde, L., 2011. Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia. *CNS Neuro* **17**, 97–103.
- Obermeier, M., Schennach-Wolff, R., Meyer, S., Möller, H.J., Riedel, M., Krause, D., Seemüller, F., 2011. Is the PANSS used correctly? A systematic review. *BMC Psychiatry* **11**, 1–5.
- Overall, J.E., Gorham, D.R., 1962. The Brief Psychiatric Rating Scale. *Psychol. Rep.* **10**, 799–812.
- Pandita, M.B.A., Lesmana, C.B.J., 2019. Prevalensi penderita skizofrenia dengan riwayat kekerasan di Rumah Sakit Jiwa Bangli Provinsi Bali. *Intisari Sains Medis* **10**, 830–833.

- Ravanic, D.B., Dejanovic, S.M.D., Janjic, V., Jovic, S.D., Milovanovic, D.R., 2009. Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period. *Arq. Neuropsiquiatr.* **67**, 195–202.
- Richelson, E., Souder, T., 2000. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. *Life Sci.* **68**, 29–39.
- Riedel, M., Müller, N., Strassnig, M., Spellmann, I., Engel, R.R., Musil, R., *et al.*, 2005. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. *Eur. Arch. Psychiatry Clin. Neurosci.* **255**, 432–437.
- Ripke, S., O’Dushlaine, C., Chambert, K., Moran, J.L., Kähler, A.K., Akterin, S., *et al.*, 2013. Genome-wide association analysis identifies 14 new risk loci for schizophrenia. *Nat. Genet.* **45**, 1150–1159.
- Rubeša, G., Gudelj, L., Kubinska, N., 2011. Etiology of schizophrenia and therapeutic options. *Psychiatr. Danub.* **23**, 308–315.
- Sahni, S., Chavan, B.S., Sidana, A., Kalra, P., Kaur, G., 2016. Comparative study of clozapine versus risperidone in treatment-naïve, first-episode schizophrenia: A pilot study. *Indian J. Med. Res.* **144**, 697–703.
- Schmitt, A., Malchow, B., Hasan, A., Falkai, P., 2014. The impact of environmental factors in severe psychiatric disorders. *Front. Neurosci.* **8**, 1–10.
- Seneca, N., Finnema, S.J., Kiss, B., Horváth, A., Pásztor, G., Kapás, M., *et al.*, 2011. Occupancy of dopamine D 2 and D 3 and serotonin 5-HT 1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. *Psychopharmacol.* **218**, 579–587.
- Shafti, S.S., Gilanipoor, M., 2014. A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia. *Schizophr. Res. Treat.* **2014**, 1–5.
- Shafti, S.S., Kaviani, H., 2015. Quetiapine versus aripiprazole in the management of schizophrenia. *Ther. Adv. Psychopharmacol.* **5**, 166–171.
- Shargel, L., Yu, A.B.C., 2016. Introduction of Biopharmaceutics and Pharmacokinetics. In: Shargel, L., Yu, A.B.C. (Eds.), *Applied Biopharmaceutics and Pharmacokinetics*. McGraw Hill Education, United State of America, pp. 4–21.
- Sharma, T., Hughes, C., Soni, W., Kumari, V., 2003. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. *Psychopharmacology (Berl)*. **169**, 398–403.
- Siafis, S., Tzachanis, D., Samara, M., Papazisis, G., 2017. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. *Curr. Neuropharmacol.* **16**, 1210–1223.
- Silvestre, J.S., Prous, J., 2005. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. *Methods Find. Exp. Clin. Pharmacol.* **27**, 289–304.
- Simeone, J.C., Ward, A.J., Rotella, P., Collins, J., Windisch, R., 2015. An evaluation of variation in published estimates of schizophrenia prevalence

- from 1990-2013: A systematic literature review. *BMC Psychiatry* **15**, 1–14.
- Singam, A.P., Mamarde, A., Behere, P.B., 2011. A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia. *Indian J. Psychol. Med.* **33**, 134–140.
- Stephenson, C.M.E., Bigliani, V., Jones, H.M., Mulligan, R.S., Acton, P.D., Visvikis, D., *et al.*, 2000. Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo: [123I]-epidepride single photon emission tomography (SPET) study. *Br. J. Psychiatry* **177**, 408–415.
- Strous, R.D., Kupchik, M., Roitman, S., Schwartz, S., Gonen, N., Mester, R., *et al.*, 2006. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: A naturalistic prospective 12-week observational study. *Hum. Psychopharmacol.* **21**, 235–243.
- Takahashi, H., Higuchi, M., Suhara, T., 2006. The Role of Extrastriatal Dopamine D2 Receptors in Schizophrenia. *Biol. Psychiatry* **59**, 919–928.
- Tuppurainen, H., Kuikka, J.T., Viinamäki, H., Husso, M., Tiihonen, J., 2009. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine: Regular article. *Psychiatry Clin. Neurosci.* **63**, 529–537.
- Üçok, A., Incesu, C., Aker, T., Erkoç, Ş., 2007. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. *Eur. Psychiatry* **22**, 328–333.
- Varese, F., Smeets, F., Drukker, M., Lieverse, R., Lataster, T., Viechtbauer, W., *et al.*, 2012. Childhood adversities increase the risk of psychosis: A meta-analysis of patient-control, prospective-and cross-sectional cohort studies. *Schizophr. Bull.* **38**, 661–671.
- Wang, J., Hu, M.R., Guo, X.F., Wu, R.R., Li, L.H., Zhao, J.P., 2013. Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients. *Neural Regen. Res.* **8**, 277–286.
- Wani, R.A., Dar, M.A., Margoob, M.A., Rather, Y.H., Haq, I., Shah, M.S., 2015. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia, before and after antipsychotic treatment. *J. Neurosci. Rural Pract.* **6**, 17–22.
- Wirshing, D.A., Spellberg, B.J., Erhart, S.M., Marder, S.R., Wirshing, W.C., 1998. Novel antipsychotics and new onset diabetes. *Biol. Psychiatry* **44**, 778–783.
- Wubeshet, Y.S., Mohammed, S.O., Desse, T.A., 2019. Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study. *BMC Psychiatry* **1**, 1–8.
- Zanella, A., Berthoud, L., Ventura, J., C.G., M.M., 2013. The Brief Psychiatric Rating Scale (version 4.0) factorial structure and its sensitivity in the treatment of outpatients with unipolar depression. *Psychiatry Res.* **210**, 626–633.
- Zygmunt, A., Olfson, M., Boyer, C.A., Mechanic, D., 2002. Interventions to improve medication adherence in schizophrenia. *Am. J. Psychiatry* **159**, 1653–1664.